Ocugen receives Nasdaq bid price deficiency notice and reports Q1 net loss of $0.07 per share

Ocugen, Inc.

Nasdaq notified Ocugen on May 1 that its stock closed below $1.00 for 30 consecutive days; 180-day cure period until Oct 30, 2023.
Cash and investments $76.7M at March 31, 2023, down from $90.9M at Dec 31, 2022; funding expected into Q1 2024.
Net loss per share $0.07 in Q1 2023 vs $0.09 in Q1 2022; total operating expenses $17.8M.
OCU400 Phase 1/2 shows positive preliminary efficacy/safety; FDA approved pediatric enrollment; Phase 3 trial planned late 2023.
COVAXIN development in North America discontinued; shift to inhaled mucosal vaccine platform (flu and COVID-19).

item 2.02 item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ocugen, Inc. reported the three months ended March 31, 2023 results: EPS $0.07 net loss per common share.

Period: the three months ended March 31, 2023
EPS: $0.07 net loss per common share
Result: reported results

Exact text from the filing

Ocugen reported a $0.07 net loss per common share for the three months ended March 31, 2023 compared to a $0.09 net loss per common share for the three months ended March 31, 2022.

View on SEC.gov

Browse all earnings releases →

Ocugen, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-015993

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.